- Home
- MYI vs SLP Comparison
MYI vs SLP Comparison
Compare MYI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- SLP
- Stock Information
- Founded
- MYI 1992
- SLP 1996
- Country
- MYI United States
- SLP United States
- Employees
- MYI N/A
- SLP N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- SLP EDP Services
- Sector
- MYI Finance
- SLP Technology
- Exchange
- MYI Nasdaq
- SLP Nasdaq
- Market Cap
- MYI 697.2M
- SLP 675.9M
- IPO Year
- MYI N/A
- SLP 1997
- Fundamental
- Price
- MYI $10.49
- SLP $16.96
- Analyst Decision
- MYI
- SLP Buy
- Analyst Count
- MYI 0
- SLP 7
- Target Price
- MYI N/A
- SLP $35.40
- AVG Volume (30 Days)
- MYI 256.7K
- SLP 603.3K
- Earning Date
- MYI 01-01-0001
- SLP 07-14-2025
- Dividend Yield
- MYI 4.81%
- SLP 0.35%
- EPS Growth
- MYI N/A
- SLP N/A
- EPS
- MYI N/A
- SLP 0.36
- Revenue
- MYI N/A
- SLP $78,564,000.00
- Revenue This Year
- MYI N/A
- SLP $27.66
- Revenue Next Year
- MYI N/A
- SLP $6.75
- P/E Ratio
- MYI N/A
- SLP $47.18
- Revenue Growth
- MYI N/A
- SLP 21.49
- 52 Week Low
- MYI $9.32
- SLP $16.72
- 52 Week High
- MYI $11.70
- SLP $44.33
- Technical
- Relative Strength Index (RSI)
- MYI 49.45
- SLP 28.76
- Support Level
- MYI $10.37
- SLP $16.75
- Resistance Level
- MYI $10.63
- SLP $18.09
- Average True Range (ATR)
- MYI 0.07
- SLP 0.81
- MACD
- MYI 0.01
- SLP 0.40
- Stochastic Oscillator
- MYI 42.86
- SLP 10.76
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.